Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 12Thoracic 2Sarcoma 1Plasma cell 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 104Carcinoma, Hepatocellular 103Stomach Neoplasms 62Pancreatic Neoplasms 46Liver Neoplasms 38Colonic Neoplasms 37Esophageal Neoplasms 28Rectal Neoplasms 22Neoplasms 13Neoplasm Metastasis 13Gastrointestinal Neoplasms 12Barrett Esophagus 11Recurrence 10Gastrointestinal Stromal Tumors 10Breast Neoplasms 10Bile Duct Neoplasms 10Pain, Postoperative 9Lung Neoplasms 8Cholangiocarcinoma 8Head and Neck Neoplasms 7Malnutrition 6Hepatitis B 6Carcinoma, Non-Small-Cell Lung 6Biliary Tract Neoplasms 6Agnosia 6Adenocarcinoma 6Prostatic Neoplasms 5Postoperative Complications 5Peptic Ulcer 5Pain 5

Interventions

Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Venous Thromboembolism × Gastrointestinal × Clear all
NCT00966277 2016-12-12

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed
87 enrolled 9 charts
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡